Skip to main content
MYUNGMOON PHARM CO.,LTD logo

MYUNGMOON PHARM CO.,LTD — Investor Relations & Filings

Ticker · 017180 ISIN · KR7017180001 KO Manufacturing
Open in API
Filings indexed 250 across all filing types
Latest filing 2019-03-22 Declaration of Voting R…
Country KR South Korea
Listing KO 017180

About MYUNGMOON PHARM CO.,LTD

http://mmpharm.co.kr/en/main/

Myungmoon Pharm Co., Ltd. is a research-based pharmaceutical company engaged in the development, manufacturing, and commercialization of healthcare products. The company produces over 250 specialized and general medicines, holding more than 400 manufacturing licenses. Its portfolio includes both ethical (ETC) and over-the-counter (OTC) drugs, with key product areas in anesthetics, digestive agents, and antitussives. The company's operations encompass the wholesale, import, and export of its pharmaceutical products for domestic and international markets.

Recent filings

Filing Released Lang Actions
정기주주총회결과
Declaration of Voting Results & Voting Rights Announcements Classification · 100% confidence The document is an official announcement of the results of a General Shareholders' Meeting (AGM) for Myungmoon Pharm. It details the approval of financial statements, director appointments, and other resolutions passed during the meeting held on March 22, 2019. This aligns perfectly with the definition of a Declaration of Voting Results & Voting Rights Announcement (DVA).
2019-03-22 Korean
감사보고서제출
Audit Report / Information Classification · 98% confidence The document is a regulatory filing from Myungmoon Pharm titled 'Audit Report Submission' (감사보고서 제출). It provides the audit opinion, key financial data (assets, liabilities, equity, profit/loss), and details regarding the external auditor. While it contains financial data, it is a summary disclosure of the audit results rather than the full 10-K annual report or a standalone audit report document. According to the classification rules, this type of summary disclosure regarding the submission of an audit report is categorized as an Audit Report / Information (AR). FY 2018
2019-03-14 Korean
주주총회소집공고
AGM Information Classification · 98% confidence The document is a 'Notice of Annual General Meeting' (주주총회소집공고) for Myungmoon Pharm Co., Ltd. It contains the meeting agenda, details on director elections, financial statements (pre-audit), and management's discussion of business operations. This type of document is standard for proxy solicitation and shareholder meeting materials, which falls under the 'Proxy Solicitation & Information Statement' category.
2019-02-28 Korean
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is a 'Proxy Solicitation & Information Statement' (PSI) filed by Myungmoon Pharm Co., Ltd. It explicitly contains information regarding the solicitation of proxies for the 33rd Annual General Meeting (AGM) scheduled for March 22, 2019. It includes details on the solicitor, the scope of shareholders, the purpose of the solicitation, and the agenda items for the meeting, including financial statements. While it contains financial data, it is structured as a formal proxy solicitation document required for shareholder voting, not a standalone annual report or earnings release.
2019-02-28 Korean
주주총회소집결의
AGM Information Classification · 98% confidence The document is a formal notice of a General Meeting (주주총회소집결의) issued by Myungmoon Pharm. It outlines the date, location, and agenda items (financial statement approval, director appointments, and articles of incorporation changes) for the upcoming Annual General Meeting. This document serves as the official proxy solicitation and meeting notice provided to shareholders, which falls under the Proxy Solicitation & Information Statement category.
2019-02-21 Korean
주주총회집중일개최사유신고
AGM Information Classification · 95% confidence The document is a formal regulatory filing submitted by Myungmoon Pharm to disclose the reason for holding their Annual General Meeting (AGM) on a 'concentrated date' (a date when many companies hold their AGMs). It explains the scheduling conflicts with auditors and management. Since it is a regulatory disclosure regarding meeting logistics rather than the meeting materials themselves, the proxy statement, or the results, it falls under the general regulatory filing category.
2019-02-21 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.